Inoue K, Mukaiyama T, Mitsui I, Ogawa M
Cancer Chemother Pharmacol. 1985;15(3):208-13. doi: 10.1007/BF00263887.
The efficacy of anticancer drugs against ovarian cancer, breast cancer, and colorectal cancer has been evaluated in vitro by the human tumor clonogenic assay developed by Hamburger and Salmon. The in vitro colony assay method used in this study is a minor modification of their method and was used in 83 patients with ovarian cancer, 47 patients with breast cancer, and 13 patients with colorectal cancer. The total numbers of assays performed in vitro were 258 for ovarian cancer, 87 for breast cancer, and 38 for colorectal cancer. The average chemosensitivity rates to single agents tested were 35% and 32% in the untreated patients with ovarian and breast cancer, respectively. In contrast to this result, the chemosensitivity rate of the untreated patients with colorectal cancer was only 16%. Consisting the clinical efficacy of anticancer drugs against these tumors, these results suggest that there is a correlation between chemosensitivity in the human tumor clonogenic assay and clinical responsiveness. In this assay the chemosensitivity in specimens from ovarian cancer patients who had had prior chemotherapy was significantly lower than in those from nonpretreated patients (P less than 0.05). This seems to indicate the development of drug resistance after treatment with anticancer drugs. These results suggest that the human tumor clonogenic assay is a useful tool for the evaluation of antitumor effects of drugs in vitro.
通过汉堡和萨尔蒙开发的人肿瘤克隆形成试验，在体外评估了抗癌药物对卵巢癌、乳腺癌和结直肠癌的疗效。本研究中使用的体外集落试验方法是对他们方法的微小改进，用于83例卵巢癌患者、47例乳腺癌患者和13例结直肠癌患者。卵巢癌体外试验的总数为258次，乳腺癌为87次，结直肠癌为38次。未经治疗的卵巢癌和乳腺癌患者对单一药物测试的平均化疗敏感性率分别为35%和32%。与该结果相反，未经治疗的结直肠癌患者的化疗敏感性率仅为16%。考虑到抗癌药物对这些肿瘤的临床疗效，这些结果表明人肿瘤克隆形成试验中的化疗敏感性与临床反应性之间存在相关性。在该试验中，曾接受过化疗的卵巢癌患者标本中的化疗敏感性明显低于未接受过治疗的患者（P小于0.05）。这似乎表明抗癌药物治疗后出现了耐药性。这些结果表明，人肿瘤克隆形成试验是体外评估药物抗肿瘤作用的有用工具。
